Development of antibodies against humanized antitumor necrosis factor and loss of efficacy in a black spider monkey with inflammatory bowel disease.
Eekman
Danielle A
DA
Department of Rheumatology, VU University Medical Centre Amsterdam, The Netherlands. d.eekman@vumc.nl
Hoyer
Mark J
MJ
van Vugt
Richard M
RM
Wolbink
Gert J
GJ
Mulder
Chris J
CJ
Dijkmans
Ben A
BA
D000068879:Adalimumab; D000818:Animals; D000836:Animals, Zoo; D000893:Anti-Inflammatory Agents / Q000276:immunology* / Q000627:therapeutic use; D000906:Antibodies / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000918:Antibody Specificity / Q000276:immunology*; D053819:Atelinae / Q000276:immunology*; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D017809:Fatal Outcome; D005260:Female; D008992:Monkey Diseases / Q000188:drug therapy / Q000276:immunology*; D017211:Treatment Failure
D000893:Anti-Inflammatory Agents; D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab